Larynx and Hypopharynx Cancer

  • Sunanda Pejavar
  • Eric K. Hansen
  • Sue S. Yom
  • Naomi R. Schechter


Larynx cancer is the most common cancer of the head and neck. Risk factors include tobacco, alcohol, betel and areca nuts, and deficiencies of iron, vitamin B12, and vitamin C. Larynx subsites: Supraglottis: suprahyoid and infrahyoid epiglottis, aryepiglottic folds, arytenoids, and false cords. Glottis: true vocal cords (TVCs) including the anterior and posterior commissures. Subglottis: extends from the lower boundary of the glottis to the inferior aspect of the cricoid cartilage.


Thyroid Cartilage Larynx Preservation Altered Fractionation Advanced Local Disease Subglottic Extension 



  1. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:571-578.PubMedCrossRefGoogle Scholar
  2. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843-50.PubMedCrossRefGoogle Scholar
  3. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952.PubMedCrossRefGoogle Scholar
  4. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.PubMedCrossRefGoogle Scholar
  5. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. Sep 2 2006;368(9538):843-854.Google Scholar
  6. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944.PubMedCrossRefGoogle Scholar
  7. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098.PubMedCrossRefGoogle Scholar
  8. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.PubMedCrossRefGoogle Scholar
  9. Garden AS. The Larynx and Hypopharynx. In: Cox JD, Ang KK, editors. Radiation oncology: rationale, technique, results. 8th ed. St. Louis: Mosby; 2003. pp. 255-281.Google Scholar
  10. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685-1690.Google Scholar
  11. Le QT, Fu KK, Kroll S, et al. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 1997;39:115-126.PubMedCrossRefGoogle Scholar
  12. Lefebvre JL, Rolland F, Tesselaar M et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009;101(3):142-52.PubMedCrossRefGoogle Scholar
  13. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-899.Google Scholar
  14. Pignon JP, Maître AL, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009 May 14. [Epub ahead of print].Google Scholar
  15. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101(7):498-506.PubMedCrossRefGoogle Scholar
  16. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715.PubMedCrossRefGoogle Scholar
  17. Trotti A, Pajak T, Emami B, et al. A randomized trial of hyperfractionation versus standard fractionation in T2 squamous cell carcinoma of the vocal cord. Int J Radiat Oncol Biol Phys 2006;66(3):S15.CrossRefGoogle Scholar
  18. Yamazaki H, Nishiyama K, Tanaka E, et al. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 2006;64(1):77-82PubMedCrossRefGoogle Scholar

Further Reading

  1. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.Google Scholar
  2. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.Google Scholar
  3. Forastiere A, Maor M, Weber R, et al. Long-term Results of Intergroup RTOG 91-11: A Phase III Trial to Preserve the Larynx -Induction Cisplatin/5-FU and Radiation Therapy versus Concurrent Cisplatin and Radiation Therapy versus Radiation Therapy, ASCO National Proceedings, 2006.Google Scholar
  4. Garden AS, Forster K, Wong PF, et al. Results of radiotherapy for T2N0 glottic carcinoma: does the “2” stand for twice-daily treatment? Int J Radiat Oncol Biol Phys 2003;55:322-328.Google Scholar
  5. Greene FL, American Joint Committee on Cancer., American Cancer Society. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.Google Scholar
  6. Lee N, Phillips TL. Cancer of the Larynx. In: Leibel SA, Phillips TL, editors. Textbook of radiation oncology. 2nd ed. Philadelphia: Saunders; 2004. pp. 679-698.Google Scholar
  7. Lefebvre JL, Ang KK. Larynx preservation consensus panel. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys. 2009;73(5):1293-1303.Google Scholar
  8. Lefebvre JL, Chevalier D, Luboinski B et al. Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 5531Google Scholar
  9. Mendenhall WM, Hinerman RW, Amdur RJ, et al. Larynx. In: Perez CA, Brady LW, Halperin EC, et al., editors. Principles and practice of radiation oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. pp. 1094-1116.Google Scholar
  10. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Available at: Accessed on May 19, 2009.
  11. Shah HK, Khuntia D, Hoffman HT, Harari PM. Hypopharynx. In: Halperin EC, Perez CA, Brady LW, et al., editors. Principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. pp. 958-974.Google Scholar
  12. Zelefsky MJ. Cancer of the Hypopharynx. In: Leibel SA, Phillips TL, editors. Textbook of radiation oncology. 2nd ed. Philadelphia: Saunders; 2004. pp. 657-678.Google Scholar

Copyright information

© Springer-Verlag New York 2010

Authors and Affiliations

  • Sunanda Pejavar
    • 1
  • Eric K. Hansen
    • 2
  • Sue S. Yom
    • 1
  • Naomi R. Schechter
    • 1
  1. 1.Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Radiation Oncology, The Oregon ClinicProvidence St. Vincent Medical CenterPortlandUS

Personalised recommendations